PACB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pacific Biosciences of California Inc (PACB) is not a strong buy for a beginner investor with a long-term focus at this time. The stock's technical indicators show a bearish trend, analysts have downgraded the stock with a reduced price target, and the company's financial performance shows significant losses despite revenue growth. Additionally, there are no strong positive catalysts or trading signals to support an immediate buy decision.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 41.517, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 1.365, with resistance at 1.43 and support at 1.3. Overall, the technical indicators suggest a bearish trend.
Gross margin improved significantly, up 154.77% YoY to 35.26%.
Net income dropped by -1802.70% YoY, and EPS fell by -1400.00% YoY. Analysts downgraded the stock to Underweight with a reduced price target of $1.50, citing competitive pressures and potential demand pauses. No significant news or congress trading data to act as a positive catalyst.
In Q4 2025, revenue increased to $44.645 million, up 13.82% YoY. However, net income dropped significantly to -$40.371 million (-1802.70% YoY), and EPS fell to -0.13 (-1400.00% YoY). Gross margin improved to 35.26%, up 154.77% YoY.
Barclays downgraded PACB to Underweight from Equal Weight, reducing the price target to $1.50 from $2. Analysts expect a near-term demand pause due to competitive launches and reduced research activity in anticipation of SPRQ NX.
